In our interview with Christine Pennington, Senior Scientist at Veloxity Labs, we discussed how the team improved the speed and efficiency of pharmacokinetic (PK) analysis to better support client decision-making.
As a bioanalytical services provider working across drug development programs, Veloxity Labs saw an opportunity to move away from a manual Excel-based workflow and adopt a more streamlined approach. The result was a faster internal process, easier reporting, and the ability to provide PK/TK parameters alongside concentration data, often on the same day.
“Aplos NCA has made PK analysis much faster and easier for us. What used to take one to two hours can now be turned around in minutes, and we’re able to provide PK/TK parameters alongside concentration data the same day, helping clients make faster study decisions. Said Christine Pennington, Senior Scientist at Veloxity Labs.
Before adopting Aplos NCA from Aplos Analytics, PK analysis at Veloxity was handled through an Excel-based workflow.
The process worked, but it came at a cost.
Every dataset required significant manual formatting before analysis could begin. From there, the team had to carefully review and check each step to ensure accuracy. This approach not only increased the workload but also introduced opportunities for transcription error.
Time quickly became the limiting factor. Preparing data and generating results typically took one to two hours. After that, internal QC checks and reviews could take several more hours. In practice, PK analysis added at least one full business day to the delivery of bioanalytical results.
For clients making interim study decisions, that delay mattered. When decisions depend on rapid access to PK or toxicokinetic (TK) parameters, speed becomes part of the value of the service itself.
The answer led them to Aplos NCA.
With a more automated and user-friendly approach, the team could move away from heavy reformatting and manual validation. Instead, they were able to import data, select the appropriate columns and designations, and generate outputs in a format that was clear, structured, and easier to use.
Just as importantly, the workflow became easier to trust.
Adopting new software often requires teams to adapt their workflows. In this case, the opposite was true.
Aplos NCA fit naturally into Veloxity’s existing reporting process. Outputs could be grouped logically and transferred directly into the team’s reporting formats, making it easier to build client-facing reports around the parameters most relevant to each study.
The platform also supported decision-making around which parameters to report for different routes of administration, adding practical value beyond calculation alone.
Implementation was straightforward. After onboarding, Aplos NCA was integrated into routine nonclinical PK analysis. The software supports data import, parameter selection, grouping, export, and reporting in a way that aligns with how the team already operates. Additionally, all actions are 21 CFR Part 11 compliant, supporting use for both non-GLP and GLP studies.
The impact of the new workflow was immediate.
What previously took one to two hours could now be completed in approximately five to ten minutes once the analysis was properly set up. In many cases, the entire process could be completed in about 30 minutes.
This shift did more than save time, it fundamentally changed how the team could operate.
Instead of being constrained by manual processing and extended review cycles, Veloxity could move quickly through PK analysis and focus more attention on higher-value work.
The internal efficiency gains translated directly into a better client experience.
Veloxity began delivering PK and TK parameters alongside concentration data, often on the same day and sometimes within hours. In one example, data received at approximately 2:00 PM was converted into completed PK/TK output by 3:00 PM.
For clients, this meant faster access to critical insights, enabling quicker decisions on dose selection, interim evaluations, and next steps within ongoing studies.
And that speed did not go unnoticed.
As turnaround times improved, client behavior began to shift.
Some customers started including PK/TK analysis in all upcoming non-GLP studies, rather than requesting it occasionally. One recurring client expanded work across multiple analytes and multiple nonclinical species, with seven studies completed and several more already in progress.
What had once been an add-on service became something clients expected, and increasingly relied on.
Internally, PK analysis evolved from something performed once or twice a year into a growing and more marketable offering.
With a platform the team could confidently use and present externally, Veloxity strengthened its position as a responsive partner. The ability to deliver faster results, combined with structured and client-ready reporting, supported a more agile and competitive bioanalytical service model.
As demand for PK analysis continues to grow, Veloxity is well positioned to make same-day or near-real-time PK reporting a standard part of its client service strategy.
The combination of faster output generation, improved reporting workflows, and responsiveness to interim study needs has made PK a more scalable and valuable component of the company’s offering.
By adopting Aplos NCA, Veloxity Labs transitioned from a manual, time-intensive PK workflow to a streamlined and efficient process that better supports both internal teams and their clients.
The ability to deliver PK/TK parameters alongside concentration data, often on the same day, has improved responsiveness, enhanced the client experience, and expanded PK into a core part of Veloxity’s service offering.